Three Key Considerations to Boost Quality of Care and Outcomes Amid Demographic Shifts
According to the World Health Organization (WHO), the pace of the population ageing is faster today than ever before. From 2015 to 2050, the number of people aged over 60 is predicted to increase from 12 per cent to 22 per cent, creating challenges for countries around the world to ensure both health and social systems can deal with what the WHO refers to as a demographic shift. Carina Van Eester at DATWYLER identifies that, as more people are diagnosed with chronic health conditions and costs continue to rise, it has never been more important to maintain the highest level of care using all available tools and resources, including parenteral packaging
Extract:
‘Addressing Value-based Care Needs with Parenteral Packaging’
According to the World Health Organization (WHO), the pace of the population aging is faster today than ever before. From 2015 to 2050, the number of people aged over 60 is predicted to increase from 12 percent to 22 percent, creating challenges for countries around the world to ensure both health and social systems are capable of dealing with what the WHO refers to as a demographic shift. To put this into perspective, the figures show that in 2050 the number of people over 60 will reach two billion globally – with the majority living in low to middle income countries – and with healthcare budgets largely decreasing. As more people are diagnosed with chronic health conditions and costs continue to rise, it has never been more important to maintain the highest level of care using all available tools and resources, including parenteral packaging.
A more holistic approach could be the solution, and many believe that value-based healthcare is the answer. In 2020, for example, value in health was identified as a priority area for the G20 nations, and the establishment of a knowledge sharing platform was welcomed by WHO Director General Dr Tedros Adhanom Ghebreyesus. The overarching theory is that by monitoring the complete journey of a patient as they progress through a healthcare system, value can be measured through assessing the entire cost of that patient’s care, the quality of that care, and the ultimate outcome.
Of course, when looking at the bigger picture – as value-based healthcare demands – value can be added from a wide range of sources, and manufacturing is a key factor to achieve the intended outcome. Thus, it is essential for device manufacturers and drug developers looking to better address the shift to value-based care to work with component manufacturers that can add value directly, through thoughtful design, material selection, and quality-driven manufacturing processes. Here, we look at three key areas of consideration in parenteral packaging selection that can support a value-based care approach to drug delivery.
Click the download button below to read the complete version of ‘Addressing Value-based Care Needs with Parenteral Packaging’ by Carina Van Eester at DATWYLER
